# OPTIMISE-CKD Study_current Clinical Landscape in Spain

> **NCT06614712** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 91628 (actual)

## Conditions studied

- Renal Disease

## Interventions

- **OTHER:** Pre-pricing & reimbursement, incident renal disease cohort (study observation period 2020- 2024)
- **OTHER:** Post-pricing & reimbursement, incident renal disease cohort (study observation period 2023-2024)

## Key facts

- **NCT ID:** NCT06614712
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-04
- **Primary completion:** 2025-10-06
- **Final completion:** 2025-10-06
- **Target enrollment:** 91628 (ACTUAL)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06614712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06614712, "OPTIMISE-CKD Study_current Clinical Landscape in Spain". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06614712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*